These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19491086)

  • 81. Optimal management of breast cancer in the elderly patient: current perspectives.
    Le Saux O; Ripamonti B; Bruyas A; Bonin O; Freyer G; Bonnefoy M; Falandry C
    Clin Interv Aging; 2015; 10():157-74. PubMed ID: 25609933
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
    Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
    Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
    Yerushalmi R; Goldvaser H; Sulkes A; Ben-Aharon I; Hendler D; Neiman V; Ciuraru NB; Bonilla L; Amit L; Zer A; Granot T; Rizel S; Stemmer SM
    PLoS One; 2014; 9(10):e107273. PubMed ID: 25330205
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
    Burkard ME; Wisinski KB; Njiaju UO; Donohue S; Hegeman R; Stella A; Mansky P; Shah V; Goggins T; Qamar R; Dietrich L; Kim K; Traynor AM; Tevaarwerk AJ
    Clin Breast Cancer; 2014 Jun; 14(3):205-11. PubMed ID: 24342730
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.
    Altwairgi AK; Hopman WM; Mates M
    Curr Oncol; 2013 Jun; 20(3):e171-9. PubMed ID: 23737687
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
    Younis T; Rayson D; Thompson K
    Support Care Cancer; 2012 Oct; 20(10):2523-30. PubMed ID: 22252548
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.
    Younis T; Rayson D; Skedgel C
    Curr Oncol; 2011 Dec; 18(6):e288-96. PubMed ID: 22184496
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
    Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
    Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
    Takabatake D; Taira N; Hara F; Sien T; Kiyoto S; Takashima S; Aogi K; Ohsumi S; Doihara H; Takashima S
    Jpn J Clin Oncol; 2009 Aug; 39(8):478-83. PubMed ID: 19491086
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
    Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
    Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.